Wire · opportunities
FDA Okays Finerenone for CKD in Adults With Type 1 Diabetes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 September 2026 · Fusion42 review
The FDA approved finerenone (Kerendia) for treating chronic kidney disease (CKD) in adults with type 1 diabetes, marking the first new treatment for this condition in over 30 years. Approval is based on positive phase 3 trial results showing reduction in urine albumin-to-creatinine ratio and expected benefits on kidney function.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 17 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
You now have a new drug approved specifically for type 1 diabetes patients with CKD, opening a fresh treatment route after decades. This creates a pathway to engage clinicians looking beyond older therapies and address a notable unmet need in renal care.
◆ Coverage
5 sources · first reported 17 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics